G protein‐coupled estrogen receptor agonist G‐1 decreases ADAM10 levels and NLRP3‐inflammasome component activation in response to Staphylococcus aureus alpha‐hemolysin

Author:

Zheng Huayu1,Triplett Kathleen D.1,Prossnitz Eric R.2,Hall Pamela R.1,Daly Seth M.1ORCID

Affiliation:

1. Department of Pharmaceutical Sciences University of New Mexico Health Sciences Center, College of Pharmacy Albuquerque New Mexico USA

2. Department of Internal Medicine, School of Medicine, Center of Biomedical Research Excellence in Autophagy, Inflammation and Metabolism and University of New Mexico Comprehensive Cancer Center University of New Mexico Health Sciences Center Albuquerque New Mexico USA

Abstract

AbstractThe G protein‐coupled estrogen receptor, also known as GPER1 or originally GPR30, is found in various tissues, indicating its diverse functions. It is typically present in immune cells, suggesting its role in regulating immune responses to infectious diseases. Our previous studies have shown that G‐1, a selective GPER agonist, can limit the pathogenesis mediated by Staphylococcus aureus alpha‐hemolysin (Hla). It aids in clearing bacteria in a mouse skin infection model and restricts the surface display of the Hla receptor, ADAM10 (a disintegrin and metalloprotease 10) in HaCaT keratinocytes. In this report, we delve into the modulation of GPER in human immune cells in relation to the NLRP3 inflammasome. We used macrophage‐like differentiated THP‐1 cells for our study. We found that treating these cells with G‐1 reduces ATP release, decreases the activity of the caspase‐1 enzyme, and lessens cell death following Hla intoxication. This is likely due to the reduced levels of ADAM10 and NLRP3 proteins, as well as the decreased display of the ADAM10 receptor in the G‐1‐treated THP‐1 cells. Our studies, along with our previous work, suggest the potential therapeutic use of G‐1 in reducing Hla susceptibility in humans. This highlights the importance of GPER in immune regulation and its potential as a therapeutic target.

Funder

National Cancer Institute

National Institute of General Medical Sciences

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3